Asklepios BioPharmaceutical
Dr. Samulski received his PhD in medical microbiology and immunology from the University of Florida. His graduate work (1978-82) demonstrated the first use of AAV as a viral vector and culminated in the first U.S. patent involving non-AAV genes inserted into AAV.
This person is not in any offices
Asklepios BioPharmaceutical
1 followers
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders.